Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd.
Your view on PAVS
Overview
What the company does, where it operates, and who runs it.
About Paranovus Entertainment Technology Ltd.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Xiaoyue Zhang
- Headquarters
- No. 11, Dongjiao East Road, New York City, CN
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Xiaoyue Zhang
- Headquarters
- No. 11, Dongjiao East Road, New York City, CN
Paranovus Entertainment Technology Ltd. engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally.
The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids.
It also offers product marketing and e-commerce agency operation services under the Happy Buy platform to small and middle size businesses; and e-commerce solutions, internet information, and advertising services to the online stores or manufactures.
In addition, the company provides secure transaction environment, automobile procurement, and financial services for automobile manufacturers under the Taochejun automobile sales platform. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand.
The company was formerly known as Happiness Development Group Limited and changed its name to Paranovus Entertainment Technology Ltd. in March 2023. Paranovus Entertainment Technology Ltd. was founded in 2004 and is headquartered in Nanping, the People's Republic of China.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Paranovus Entertainment Technology Ltd. from FRC's valuation model, read against the market price. PAVS last traded at $2.90; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Paranovus Entertainment Technology Ltd.. Starting points for Paranovus Entertainment Technology Ltd.: EPS -$7948.70, beta -0.14 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Paranovus Entertainment Technology Ltd.. Paranovus Entertainment Technology Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Paranovus Entertainment Technology Ltd.. Trailing twelve-month EPS for Paranovus Entertainment Technology Ltd. stands at -$7948.70. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings Estimate
| EPS | Current YearFY Mar 2027 | Next YearFY Mar 2028 |
|---|---|---|
| Avg. estimate | $2,112,000.00 | $2,112,000.00 |
| Low estimate | $2,112,000.00 | $2,112,000.00 |
| High estimate | $2,112,000.00 | $2,112,000.00 |
| No. of analysts | 1 | 1 |
| Year-ago EPS | -$1,516.10 | — |
| Growth | +139404.8% | — |
Revenue Estimate
| Revenue | Current YearFY Mar 2027 | Next YearFY Mar 2028 |
|---|---|---|
| Avg. estimate | $72.22M | $72.22M |
| Low estimate | $72.22M | $72.22M |
| High estimate | $72.22M | $72.22M |
| No. of analysts | 1 | 1 |
| Year-ago revenue | $23.33M | — |
| Growth | +209.6% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Paranovus Entertainment Technology Ltd.. Paranovus Entertainment Technology Ltd. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Paranovus Entertainment Technology Ltd. valued side by side against its closest peers. Paranovus Entertainment Technology Ltd. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Paranovus Entertainment Technology Ltd. executives and directors. Shares of Paranovus Entertainment Technology Ltd. have traded between $0.43 and $1.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Paranovus Entertainment Technology Ltd.. Coverage tracks Paranovus Entertainment Technology Ltd. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Paranovus Entertainment Technology Ltd.